[A22-08] Vericiguat (cardiac failure) - Addendum to Commission A21-120
Last updated 03.03.2022
Project no.:
A22-08
Commission:
Commission awarded on 25.01.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Adults with symptomatic chronic heart failure with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy
Unchanged after addendum:
- Age < 75 years: hint of a non-quantifiable added benefit
- Age ≥ 75 years: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-120 | Vericiguat (cardiac failure) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-03-03 A G-BA decision was published.